Figure 4 from Exploiting Natural Killer Cell Engagers to Control Pediatric B-cell Precursor Acute Lymphoblastic Leukemia

Résumé fourni par la source

CD19-NKCEs efficiently promote NK-cell antileukemia activity in a transplantation setting. A, Evaluation of NKp46, NKp30, CD16, perforin, and granzyme B expression in NK cells from transplanted patients (Post1–3M; n = 12) and healthy donors (HD; n = 5–11). B, Representative experiment of cytototoxicity (7AAD/AnnV staining). MHH-CALL-4 or ALL#06 primary leukemia target cells were cultured either alone (only target) or with resting NK cells from a transplanted patient (3 months after haplo-HSCT) and the indicated NKCEs (100 μg/mL). Numbers indicate the percentage of cells in each quadrant. Percent of specific lysis (7AAD/AnnV staining; C) and CD107a degranulation of resting NK cells (D) from transplanted patients against MHH-CALL-4 (left) or primary leukemia blasts (ALL#04 and ALL#06; right) in the presence of the indicated NKCE at 100 μg/mL. Pooled data obtained with primary leukemia blasts are shown. Results from 5–8 independent experiments are reported. The incubation time for all the tests was 4 hours. Bar show mean ± SEM. Statistical significance: *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. Mann–Whitney test was used to calculate statistical differences.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.